Ching-Dong Wang Discloses Investment at SL Science Holding Ltd with 59.53% Stake

Ching-Dong Wang disclosed a 59.53% stake in SL Science Holding Ltd’s ordinary shares. The filing on Jun. 18, 2026 follows the June 12 closing of the company’s business combination with Horizon Space Acquisition II Corp. The stake results from merger consideration and gives Wang majority voting power through SL Link Holding Ltd. and SL Link Co., Ltd.

Investor Intent

Wang received the shares through SL Bio’s merger with Horizon Space Acquisition II Corp., which created SL Science Holding Ltd as the public parent. He notes that he and his affiliates "received approximately 333,832,129 Ordinary Shares" at closing. The position reflects the equity issued in the transaction rather than open-market buying, and concentrates control with Wang and his affiliated entities.

At this time, Wang does not plan governance or strategic changes at the company and outlines no transactions like asset sales or recapitalizations. He leaves the door open to adjust his position and "may from time to time acquire additional Ordinary Shares," depending on future conditions. He also signals flexibility to buy or sell shares in the market or privately while he monitors the company’s progress after the merger.

Investor's Background

Ching-Dong Wang is a Taiwan-based executive who serves as chief executive officer, director, and chairman of SL Science Holding Ltd. He controls SL Link Holding Ltd. and leads SL Link Co., Ltd., entities through which he holds most of his ownership. Wang focuses on scaling the combined life sciences business following the merger and now holds majority control of the company.

Original SEC Filing: SL Science Holding Ltd [ SLBT ] - SCHEDULE 13D - Jun. 18, 2026